Biohaven and Pfizer announce results of rimegepant trial for acute treatment of migraine
This is the fourth positive phase-III study of rimegepant for the acute treatment of migraine, and the first to be conducted in the Asia Pacific.
February 15, 2022
by ExpressPharma
Vitamin D Supplementation Could Reduce Migraine Headache Attacks
Vitamin D supplementation could reduce headache attacks per month and headache days per month among migraine patients, according to a review published in the December issue of The American Journal of Emergency Medicine.
January 10, 2022
by drugs
Mindfulness-Based Cognitive Therapy Beneficial in Migraine
A migraine-specific adaptation of the Mindfulness-Based Cognitive Therapy (MBCT) program does not improve headache-related impairment...
January 10, 2022
by drugs
Pfizer and Biohaven close collaboration agreements
pfizer has completed the collaboration transaction with Biohaven Pharmaceuticals to obtain rights to market the latter’s rimegepant and zavegepant outside of the US.
January 6, 2022
by pharmaceutical-business-review
Hormone exposure in the womb potentially linked to migraine risk in later life
Hormone levels in the womb before birth have been potentially linked to the risk of developing migraine in adulthood, reveals a new study of genetic and environmental information from the world's largest database of twins.
December 17, 2021
by FirstWordPharma
Patients benefited from telemedicine during COVID-19, says new white paper from Healint
A new white paper from healthcare analytics platform provider Healint shows that most patients with migraine and other comorbidities had positive experiences with telemedicine, especially during the COVID-19 pandemic.
November 12, 2021
by prnasia
BioDelivery Sciences to Acquire U.S. and Canadian Rights to ELYXYB™ for Migraine Treatment
BioDelivery Sciences International Inc., a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, announced that it entered into an agreement on August 3, 2021 with Dr. Reddy’s Laboratories ...
August 5, 2021
by americanpharmaceuticalreview
Lilly plans head-to-head migraine study comparing Emgality with Nurtec ODT
Eli Lilly is planning to conduct a head-to-head study comparing its calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) Emgality with Biohaven Pharmaceuticals’ Nurtec for the preventative treatment of migraine.
June 18, 2021
by pharmatimes
A Real Headache: Racism Plays Role in Migraine Care
The color of your skin may very well determine how your headache gets treated, a new study warns.
June 11, 2021
by drugs
FDA Approves Biohaven's NURTEC® ODT: First and Only Migraine Medication for both Acute and Preventive Treatment
Biohaven Pharmaceutical Holding Company announced that the U.S. FDA has approved NURTEC® ODT (rimegepant 75 mg) for the preventive treatment of migraine.
June 2, 2021
by americanpharmaceuticalreview
Impel NeuroPharma Expands Commercial Team
Prepares for the potential launch of TRUDHESA for the acute treatment of migraine headaches, pending FDA approval.
March 3, 2021
by contractpharma
FDA Approves Nerivio for Acute Treatment of Migraine in Adolescents
Theranica announced its Nerivio® therapeutic device has received the U.S. Food and Drug Administration (FDA) clearance to market for an expanded indication for acute treatment of episodic or chronic migraine in people 12 years and older.
January 26, 2021
by americanpharmaceuticalreview